University of California researchers report that they have found a new class of drugs that could lead to a pain relief treatment for people who have diabetic neuropathy. The drugs, which were successfully tested on lab animals, are anti-inflammatory compounds that inhibit the action of an enzyme called soluble epoxide hydrolase. The enzyme is key to the transmission of pain sensations. Previous research has shown that inhibiting soluble epoxide hydrolase also lowers blood pressure and protects against kidney damage.
SAN DIEGO - June 15, 2012 - Dexcom, the leader in continuous glucose monitoring, is proudly sponsoring the efforts of the Diabetes Formation Flight USA(DFFUSA.org) - three pilots with insulin-dependent diabetes using Dexcom's Seven Plus as part of their effort to set new transcontinental world speed records while raising funds for the Juvenile Diabetes Research Foundation (JDRF).
The US Food and Drug Administration has approved the use of Novo Nordisk's Levemir basal insulin for type 1 children aged two to five years. The FDA decision makes Levemir (insulin detemir [rDNA origin]) the only basal insulin approved for use in this age group. Levemir, introduced to the US market in 2006, was previously approved for older children and adults with type 1 diabetes, as well as insulin-using type 2s.
Novo Nordisk's new variety of long-lasting insulin, insulin degludec, reduces low blood sugars while improving overall control, according to a pair of studies published in the prestigious journal The Lancet on April 27.
The US Food and Drug Administration has okayed US sales of Bayer HealthCare's CONTOUR® Next EZ blood glucose monitoring system. The new BGM, currently available in other countries as the CONTOUR XT, will be available in the US market this summer.
NeuroMetrix, Inc., a Massachusetts-based medical device company, has filed a 510(k) form with the US Food and Drug Administration for the SENSUSTM, a pain therapy device for people who suffer diabetic neuropathy. A 510(k) is a "premarket notification" of a company's intent to market a medical product. The FDA then tests the product and provides feedback to the manufacturer. Once the FDA clears the product, its maker can introduce it to the US market.
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.